BDX — BCAL Diagnostics Income Statement
0.000.00%
Last trade - 00:00- AU$27.65m
- AU$32.98m
- AU$2.55m
Annual income statement for BCAL Diagnostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.719 | 2.85 | 3.1 | 2.83 | 2.55 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.1 | 7.9 | 9.4 | 9.98 | 9.57 |
| Operating Profit | -3.39 | -5.05 | -6.3 | -7.15 | -7.02 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.39 | -5.06 | -6.4 | -7.24 | -7.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.39 | -5.06 | -6.4 | -7.24 | -7.37 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.39 | -5.06 | -6.4 | -7.24 | -7.37 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.39 | -5.06 | -6.4 | -7.24 | -7.37 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.016 | -0.024 | -0.025 | -0.02 | -0.02 |